Evidence map›Paper›PMID 41195096›Full record

ReviewReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025

Preoperative accelerated hypofractionated radiotherapy (PHYPORT): state of art and potential clinical application.

Giuseppe Iatì, Silvana Parisi, Anna Maria Attisano, Issa Shteiwi, Fabiana Quattrone, Antonio Pontoriero, Anna Santacaterina, Giacomo Ferrantelli, Stefano Pergolizzi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giuseppe IatìRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy.
Silvana ParisiRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy.
Anna Maria AttisanoRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy.
Issa ShteiwiRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy.
Fabiana QuattroneUniversity of Pavia, Pavia, Italy.
Antonio PontorieroRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy.
Anna SantacaterinaRadiation Oncology Unit, Papardo Hospital, Messina, Italy.
Giacomo FerrantelliRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy.
Stefano PergolizziRadiation Oncology Unit, Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypofractionation is a radiotherapy regimen that uses fewer fractions with higher doses with respect to conventional regimen. It can reduce overall treatment time and costs. Preoperative accelerated hypofractionated radiotherapy (PHYPORT) is a new approach in which radiation therapy is delivered in fewer, larger doses over a shorter period of time before surgery and it can be used to shrink tumours before surgical removal in some cancers. The choice of hypofractionated radiotherapy depends on the type of tumour, its localization and total target volume. Also, it is important to assess the potential benefits and risks of higher radiation doses. PHYPORT could be a more convenient and cost-effective option, but its effectiveness is unclear. This review assesses the use of PHYPORT in cancer treatment.

Indexed as

breast cancerhypofractionated radiotherapyneoadjuvantpancreatic cancerPHYPORTpreoperativerectal cancersarcoma

Identifiers

PMID41195096
PMCPMC12585113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.